Estrogen, predominantly via estrogen receptor α, attenuates postpartum-induced anxiety- and depression-like behaviors in female rats. 2013

Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
PhD, Department of Physiology, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa 216-8511, Japan. mfuruta@marianna-u.ac.jp.

Contributions from estrogen receptor (ER) subtypes (ERα and ERβ) to postpartum anxiogenic and depressive responses remain unresolved in rats. Using the elevated-plus maze (EPM) and forced swim (FS) tests, we confirmed that primiparous rats exhibited anxiogenic and depressive responses 3 weeks postpartum, improved 5 weeks postpartum (EPM), and recovered at 5 (FS) or 10 weeks postpartum (EPM) compared with diestrus nulliparous females. Immunohistochemistry suggested that these behavioral changes were temporally associated with decreased ERα but not ERβ expression in the medial amygdala (MEA). Additionally, ERα expression in the medial preoptic area (MPOA) significantly increased 10 weeks postpartum. Brain-derived neurotrophic factor (BDNF) expression was significantly elevated in the MEA 3 weeks postpartum. BDNF receptor tropomyosin-related kinase expression was significantly elevated in the MEA at 3 and 10 weeks but not at 5 weeks postpartum. The phosphorylation of ERK (pERK)-2 in the MEA, MPOA, and hippocampal CA1 region was significantly elevated 3 and 5 weeks postpartum. The effects of single daily sc injections of the ERα-selective agonist, propyl pyrazoletriol (PPT); ERβ-selective agonist, diarylpropionitrile; 17β-estradiol (E₂); and vehicle for 6 days in primiparous rats were assessed. PPT and E₂ significantly produced anxiolytic and antidepressant actions in the EPM and FS tests but PPT to a lesser degree than E₂ in the EPM test. Diarylpropionitrile affected the EPM test but was not significantly different from vehicle. BDNF expression was significantly increased 3 weeks postpartum by all treatments in the MPOA but not the CA1 and MEA. E₂ and PPT treatment significantly increased tropomyosin-related kinase and pERK1/2 expression in the MEA and MPOA and increased pERK1/2 expression in the CA1. The onset of anxiety- and depression-like behaviors in postpartum rats may be partly caused by a complex estrogen-mediated mechanism; nevertheless, changes in the ERα-related system, likely in the MEA, are predominantly involved.

UI MeSH Term Description Entries
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D011301 Preoptic Area Region of hypothalamus between the ANTERIOR COMMISSURE and OPTIC CHIASM. Area Preoptica,Lateral Preoptic Area,Medial Preoptic Area,Preoptic Nuclei,Area Preopticas,Area, Lateral Preoptic,Area, Medial Preoptic,Area, Preoptic,Areas, Lateral Preoptic,Areas, Medial Preoptic,Areas, Preoptic,Lateral Preoptic Areas,Medial Preoptic Areas,Nuclei, Preoptic,Nucleus, Preoptic,Preoptic Area, Lateral,Preoptic Area, Medial,Preoptic Areas,Preoptic Areas, Lateral,Preoptic Areas, Medial,Preoptic Nucleus,Preoptica, Area,Preopticas, Area
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D000679 Amygdala Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system. Amygdaloid Body,Amygdaloid Nuclear Complex,Amygdaloid Nucleus,Archistriatum,Corpus Amygdaloideum,Intercalated Amygdaloid Nuclei,Massa Intercalata,Nucleus Amygdalae,Amygdalae, Nucleus,Amygdaloid Bodies,Amygdaloid Nuclear Complices,Amygdaloid Nuclei, Intercalated,Amygdaloid Nucleus, Intercalated,Amygdaloideum, Corpus,Amygdaloideums, Corpus,Archistriatums,Complex, Amygdaloid Nuclear,Complices, Amygdaloid Nuclear,Corpus Amygdaloideums,Intercalata, Massa,Intercalatas, Massa,Intercalated Amygdaloid Nucleus,Massa Intercalatas,Nuclear Complex, Amygdaloid,Nuclear Complices, Amygdaloid,Nuclei, Intercalated Amygdaloid,Nucleus, Amygdaloid,Nucleus, Intercalated Amygdaloid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant

Related Publications

Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
May 2019, Journal of psychopharmacology (Oxford, England),
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
May 2022, Neuroscience letters,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
April 2016, Psychoneuroendocrinology,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
January 2023, Biological & pharmaceutical bulletin,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
April 2019, Psychopharmacology,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
September 2016, Behavioural brain research,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
November 2021, Saudi journal of biological sciences,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
October 2019, Behavioural brain research,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
December 2013, Behavioral and brain functions : BBF,
Miyako Furuta, and Tadahiro Numakawa, and Shuichi Chiba, and Midori Ninomiya, and Yu Kajiyama, and Naoki Adachi, and Tatsuo Akema, and Hiroshi Kunugi
October 2011, Journal of microbiology and biotechnology,
Copied contents to your clipboard!